The AKT inhibitor MK-2206 is in phase II and is mainly used for the treatment of non-small cell lung cancer, colorectal cancer, while also exhibiting a therapeutic effect on DLBCL. This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.